[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Kim YS, Cha SJ, Choi YS, Kim BG, Park SJ, Chang IT: Retroperitoneal desmoplastic small round cell tumor: pediatric patient treated with multimodal therapy. World J Gastroenterol; 2009 Sep 7;15(33):4212-4
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal desmoplastic small round cell tumor: pediatric patient treated with multimodal therapy.
  • A desmoplastic small round cell tumor (DSRCT) is a rare, aggressive mesenchymal neoplasm.
  • Multimodal treatment with surgery, chemotherapy and radiotherapy is very important for these rare cases, and this treatment can improve patient survival.
  • The patient has undergone surgical resection and adjuvant chemoradiation therapy, and is currently alive without disease recurrence.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol. 2000 Aug;9(2):77-81 [11094327.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(3):199-202 [12094954.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jun;53(6):482-8 [14999430.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):583-6 [16643996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] J Pediatr Surg. 2005 Jan;40(1):251-5 [15868593.001]
  • [Cites] Eur J Radiol. 2005 Jun;54(3):438-42 [15899348.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1753-6 [7512439.001]
  • (PMID = 19725162.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2738824
  •  go-up   go-down


2. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM: Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res; 2007 Mar 15;13(6):1783-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
  • PURPOSE: Heat shock protein 90 (Hsp90) is essential for the posttranslational control of many regulators of cell growth, differentiation, and apoptosis.
  • We conducted a phase I trial of 17-AAG in pediatric patients with recurrent or refractory neuroblastoma, Ewing's sarcoma, osteosarcoma, and desmoplastic small round cell tumor to determine the maximum tolerated dose, define toxicity and pharmacokinetic profiles, and generate data about molecular target modulation.
  • 17-AAG pharmacokinetics in pediatric patients were linear; clearance and half-life were 21.6 +/- 6.21 (mean +/- SD) L/h/m(2) and 2.6 +/- 0.95 h, respectively.
  • Caution should be used in treatment of patients with bulky pulmonary disease.
  • [MeSH-major] Benzoquinones / administration & dosage. Benzoquinones / pharmacokinetics. Lactams, Macrocyclic / administration & dosage. Lactams, Macrocyclic / pharmacokinetics. Neoplasms / drug therapy. Pediatrics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Male. Maximum Tolerated Dose. Recurrence. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • (PMID = 17363533.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR-00069; United States / NCRR NIH HHS / RR / M01 RR-00082; United States / NCRR NIH HHS / RR / M01 RR-00095; United States / NCI NIH HHS / CA / U54 CA090821
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Biomarkers, Tumor; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin
  •  go-up   go-down


3. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F: Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant; 2001 Sep;28(6):551-6
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one patients with poor-prognosis tumors and intact function of key organs received topotecan 2 mg/m2 by 30-min intravenous (i.v.) infusion on days -8, -7, -6, -5, -4; thiotepa 300 mg/m2 by 3 h i.v. infusion on days -8, -7, -6; and carboplatin by 4 h i.v. infusion on days -5, -4, -3 with a daily dose derived from the pediatric Calvert formula, using a targeted area under the curve of seven mg/ml* min ( approximately 500 mg/m2/day).
  • Stem cell rescue was on day 0.
  • Post-transplant treatment included radiotherapy alone (four patients) or plus biological agents (11 patients with neuroblastoma).
  • With a follow-up of 6+ to 32+ (median 11+) months, event-free survivors include 10/11 neuroblastoma patients (first CR), 4/5 brain tumor patients (second PR or CR), 1/3 patients with metastatic Ewing's sarcoma (first or second CR), and a patient transplanted for multiply recurrent immature ovarian teratoma; a patient with desmoplastic small round-cell tumor (second PR) had progressive disease at 8 months.
  • Favorable results for disease control, manageable toxicity, and the antitumor profiles of topotecan, thiotepa, and carboplatin, support use of this three-drug regimen in the treatment of neuroblastoma and brain tumors; applicability to other tumors is still uncertain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Carboplatin / administration & dosage. Neuroblastoma / drug therapy. Thiotepa / administration & dosage. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11607767.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Karavitakis EM, Moschovi M, Stefanaki K, Karamolegou K, Dimitriadis E, Pandis N, Karakousis CP, Tzortzatou-Stathopoulou F: Desmoplastic small round cell tumor of the pleura. Pediatr Blood Cancer; 2007 Sep;49(3):335-8
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor of the pleura.
  • Desmoplastic small round cell tumor (DSRCT) is a rare neoplasm with aggressive behavior.
  • Since less than 10 cases of primary DSRCT in the pleura have been described, it is of interest to report a pediatric case arising from the pleura.
  • The diagnosis was confirmed by molecular detection of the EWS/WT-1 fusion gene product.
  • Multidisciplinary treatment with chemotherapy, radiotherapy, and surgical resection resulted in a progression-free survival time above the median survival, suggesting that this conventional approach could prove effective for this rare and very aggressive malignancy.
  • [MeSH-minor] Biomarkers, Tumor. Child. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16429445.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 20
  •  go-up   go-down


5. Hayes-Jordan A, Anderson P, Curley S, Herzog C, Lally KP, Green HL, Hunt K, Mansfield P: Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. J Pediatr Surg; 2007 Aug;42(8):E29-32
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor.
  • Desmoplastic small round cell tumor (DSRCT) is a rare disease of children, adolescents, and young adults that begins and spreads on the peritoneal surfaces.
  • Desmoplastic small round cell tumor usually presents with diffuse abdominal metastatic disease similar in gross appearance to carcinomatosis.
  • To date, very aggressive treatment programs have yielded dismal outcomes.
  • These are the first pediatric case reports of DSRCT being treated with continuous hyperthermic peritoneal perfusion, a procedure usually used in treatment of adult carcinomatosis.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706484.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Thijs AM, van der Graaf WT, van Herpen CM: Temsirolimus for metastatic desmoplastic small round cell tumor. Pediatr Blood Cancer; 2010 Dec 15;55(7):1431-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temsirolimus for metastatic desmoplastic small round cell tumor.
  • Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive neoplasm that mostly occurs in young males.
  • No curative treatment options currently exist for this type of tumor and long-term survival remains poor.
  • In vitro rapamycin induces apoptotic death of JN-DSRCT-1 cells, a possible model for desmoplastic small round cell tumors in which the EWS gene is fused to the WT1 gene.
  • [MeSH-major] Abdominal Neoplasms / pathology. Antineoplastic Agents / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Sirolimus / analogs & derivatives. TOR Serine-Threonine Kinases / antagonists & inhibitors
  • [MeSH-minor] Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Young Adult

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730888.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


7. Saab R, Khoury JD, Krasin M, Davidoff AM, Navid F: Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience. Pediatr Blood Cancer; 2007 Sep;49(3):274-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience.
  • BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare, primarily intra-abdominal tumor that has a poor outcome with current therapies.
  • PROCEDURE: We retrospectively reviewed patient characteristics, presenting symptoms, tumor pathology, treatment, and outcome of 11 pediatric patients with DSRCT at our institution.
  • In eight (73%) patients, the primary tumor was abdominal or pelvic, and in one patient each, it was submental, mediastinal, and paratesticular.
  • One tumor showed rhabdomyoblastic differentiation after therapy.
  • All patients received chemotherapy; eight underwent surgical resection, seven received primary site radiation, and four received myeloablative chemotherapy with stem-cell support.
  • Two died of treatment-related toxicity, six died of disease.
  • None of the patients in whom surgery and initial chemotherapy failed to induce complete remission survived.
  • CONCLUSIONS: DSRCT is an aggressive malignancy that does not respond well to contemporary treatments, and patients who do not enter complete remission after initial chemotherapy and surgery appear to have a particularly dismal outcome.
  • Better understanding of molecular and genetic mechanisms of tumorigenesis and treatment-related changes may contribute to development of more effective therapy for DSRCT.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / therapy. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Oncogene Proteins, Fusion. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16685737.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


8. Ferrari A, Grosso F, Stacchiotti S, Meazza C, Zaffignani E, Marchianò A, Casanova M: Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Pediatr Blood Cancer; 2007 Nov;49(6):864-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor.
  • We report two cases of abdominal desmoplastic small round cell tumor (DSRCT) that showed a clinical response to the vinorelbine/low-dose cyclophosphamide combination that has been claimed to be effective for rhabdomyosarcoma.
  • This observation may prompt further investigation into the activity of such a regimen in DSRCT patients with recurrent or refractory disease, with a view to a possible future role as maintenance therapy in controlling minimal residual disease in patients who achieve complete remission with intensive induction multimodality therapy.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Sarcoma, Small Cell / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Cyclophosphamide / administration & dosage. Humans. Male. Neoplasm Metastasis. Neoplasm, Residual. Remission Induction. Rhabdomyosarcoma / drug therapy

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16302215.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Baz W, El-Soueidi R, Nakhl F, Aoun N, Chin N, Dhar M: Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange. Jpn J Clin Oncol; 2010 Jun;40(6):593-5
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange.
  • Desmoplastic small round-cell tumor is an uncommon, highly aggressive tumor with a predilection for pediatric age groups and young adults.
  • Although Agent Orange has been associated with soft-tissue sarcoma, an association with desmoplastic small round-cell tumor has not been reported.
  • Computed tomography scan of the chest, abdomen and pelvis demonstrated extensive mediastinal and retroperitoneal adenopathy, diffuse omental masses and extensive pleural, intra-abdominal and pelvic ascites.
  • Omental core needle biopsy was consistent with desmoplastic small round-cell tumor based on morphology and immunohistochemistry.
  • He responded poorly to chemotherapy with high-dose cyclophosphamide, doxorubicin and vincristine and died 5 months after presentation secondary to neutropenic sepsis despite G-CSF support and antibiotics.
  • [MeSH-major] 2,4,5-Trichlorophenoxyacetic Acid / adverse effects. 2,4-Dichlorophenoxyacetic Acid / adverse effects. Abdominal Neoplasms / chemically induced. Defoliants, Chemical / adverse effects. Sarcoma, Small Cell / chemically induced. Tetrachlorodibenzodioxin / adverse effects. Veterans. Vietnam Conflict

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • Hazardous Substances Data Bank. 2,4,5-T .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382635.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Defoliants, Chemical; 2577AQ9262 / 2,4-Dichlorophenoxyacetic Acid; 39277-47-9 / Agent Orange; 9Q963S4YMX / 2,4,5-Trichlorophenoxyacetic Acid; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


10. Hayes-Jordan A, Green H, Fitzgerald N, Xiao L, Anderson P: Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. J Pediatr Surg; 2010 May;45(5):1000-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion.
  • BACKGROUND: Less than 200 cases have been reported in the world literature since desmoplastic small round cell tumor (DSRCT) was first described in 1989.
  • To date, chemotherapy, radiation therapy, and surgery have resulted in a poor survival of 30% to 55%.
  • We used hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of complete tumor resection as an adjunct to treatment of pediatric and adolescent patients with DSRCT.
  • Eight patients undergoing cytoreductive surgery and HIPEC were compared with 16 historical controls that had chemotherapy +/- radiation therapy or surgery alone.
  • CONCLUSION: Hyperthermic intraperitoneal chemotherapy is safe in children with DSRCT.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Hypothermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Female. Humans. Infusions, Parenteral. Male. Multivariate Analysis. Neoplasm Staging. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20438942.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bisogno G, Ferrari A, Rosolen A, Alaggio R, Scarzello G, Garaventa A, Arcamone G, Carli M: Sequential intensified chemotherapy with stem cell rescue for children and adolescents with desmoplastic small round-cell tumor. Bone Marrow Transplant; 2010 May;45(5):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential intensified chemotherapy with stem cell rescue for children and adolescents with desmoplastic small round-cell tumor.
  • The RMS4.99 study was designed to explore the role of early sequential intensified chemotherapy (SICT) with PBSC rescue in patients with soft tissue sarcoma with a poor prognosis.
  • Fourteen patients with desmoplastic small round-cell tumor (DSRCT) were included in this study.
  • Initial chemotherapy was followed by a course of CY and etoposide with subsequent PBSC harvest, then three consecutive intensified chemotherapy combinations followed by PBSC rescue and G-CSF administration: first cycle thiotepa (150 mg/m(2) x 2 on day 1) and melphalan (60 mg/m(2) on day 2), second cycle CY (2 g/m(2) on days 1 and 2) and thiotepa (150 mg/m(2) x 2 on day 3), third cycle melphalan (80 mg/m(2) on day 1).
  • The prognosis for pediatric patients with DSRCT did not improve after administering intensified chemotherapy early in their treatment, so different strategies are needed.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peripheral Blood Stem Cell Transplantation. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Pilot Projects. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19802018.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg; 2005 Jan;40(1):251-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodal treatment for desmoplastic small round cell tumors.
  • PURPOSE: Desmoplastic small round cell tumors (DSRCTs) are rare aggressive neoplasms that frequently present with large symptomatic intraabdominal masses.
  • We examined the effects of multimodal therapy including induction chemotherapy, aggressive surgical debulking, and external beam radiotherapy on patients with DSRCT.
  • Data were collected on patient demographics, presenting symptoms, tumor location and extent, treatment regimen, and overall survival.
  • In 63 patients (96%), the primary tumor was located in the abdomen or pelvis.
  • Twenty-nine of these patients (44%) underwent induction chemotherapy (P6), surgical debulking, and radiotherapy.
  • Three-year survival was 55% in those receiving chemotherapy, surgery, and radiotherapy vs 27% when all 3 modalities were not used (P < .02).
  • Gross tumor resection was highly significant in prolonging overall survival; 3-year survival was 58% in patients treated with gross tumor resection compared to no survivors past 3 years in the nonresection cohort (P < .00001).
  • CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT.
  • [MeSH-major] Sarcoma, Small Cell / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Neoplasms / therapy. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / therapy. Radiotherapy. Surgical Procedures, Operative. Survival Analysis. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Testicular Neoplasms / therapy. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Thoracic Neoplasms / therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Tettoni K, Provenzi M, Fossati Bellani F, Carli M: Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol. J Clin Oncol; 2004 Jul 15;22(14_suppl):8540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol.
  • The study was performed in the view of utilizing this treatment as maintenance therapy in the future European protocol for high risk RMS patients.
  • There was a median of 2 prior regimens (range 1-4); 5 patients previously received high dose chemotherapy with PBSC rescue and 12 prior radiotherapy.
  • Among 5 patients treated at dose level 4 (VNB 30 mg/m<sup>2</sup>) 2 dose limiting toxicities (grade 4 neutropenia) were observed in the first 2 cycles therefore a decision was made to enter 3 more patients at dose level 3.
  • Four patients were still on treatment after 5-10 cycles.
  • Partial responses were observed in 7/17 assessable patients: 3/8 RMS (2 embryonal, 1 alveolar), 1/1 clear cell sarcoma, 1/2 synovial sarcoma, 1/2 desmoplastic small round cell tumor, 1/1 osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013816.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kurre P, Felgenhauer JL, Miser JS, Patterson K, Hawkins DS: Successful dose-intensive treatment of desmoplastic small round cell tumor in three children. J Pediatr Hematol Oncol; 2000 Sep-Oct;22(5):446-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful dose-intensive treatment of desmoplastic small round cell tumor in three children.
  • Desmoplastic small round cell tumor (DSRCT) is a rare soft tissue tumor of primitive origin occurring primarily in children and young adults.
  • Based on published reports in the literature, the response to conventional chemotherapy is poor.
  • We report three pediatric patients successfully treated with dose-intensive, multimodal therapy.
  • All patients received a combined modality protocol including dose-intensive chemotherapy (two of them with peripheral blood stem cell [PBSC] support), second look surgery, and consolidative local irradiation.
  • Two of our patients were younger than any previously reported patient, extending the age group for which DSRCT should be considered on diagnosis of small round cell tumors.
  • The uniform survival achieved in our series indicates potential benefit for the combination of dose-intensive multiagent chemotherapy, local irradiation, and aggressive surgical approach in this disease.
  • [MeSH-major] Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child, Preschool. Combined Modality Therapy. Female. Humans. Male

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037858.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Livaditi E, Mavridis G, Soutis M, Papandreou E, Moschovi M, Papadakis V, Stefanaki K, Christopoulos-Geroulanos G: Diffuse intraabdominal desmoplastic small round cell tumor: a ten-year experience. Eur J Pediatr Surg; 2006 Dec;16(6):423-7
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intraabdominal desmoplastic small round cell tumor: a ten-year experience.
  • BACKGROUND: Intraabdominal desmoplastic small round cell tumors (IDSRCT) are rare in children and predominantly affect male adolescents and young adults.
  • We present our experience in the management of five children with diffuse IDSRCT, managed with aggressive chemotherapy, surgery, radiotherapy and peripheral blood stem cell transplantation.
  • Three patients with inoperable tumor on admission were submitted initially to open biopsy followed by aggressive chemotherapy.
  • Regression of the tumor was followed by a second laparotomy and radical excision of any macroscopically distinguishable masses, followed by chemotherapy.
  • In the remaining two patients a debulking procedure was done initially, followed by chemotherapy.
  • RESULTS: Three patients who had radical excision of the tumor and adjuvant chemotherapy had recurrence after two to six months.
  • In addition, one patient with recurrence received radiotherapy and two others underwent peripheral blood stem cell transplantation.
  • The last patient, who was submitted to a debulking procedure, is still alive eight months after the operation.
  • CONCLUSIONS: Intrabdominal desmoplastic small round cell tumor is a highly aggressive malignancy with a very poor prognosis.
  • Multiagent chemotherapy usually leads initially to a temporary regression of the tumor, but recurrence is the rule.
  • Radical surgical excision, radiotherapy and peripheral blood stem cell transplantation does not seem to improve prognosis significantly.
  • Despite all therapeutic modalities the outcome is dismal and surgical efforts can be considered only as palliative.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Female. Hematopoietic Stem Cell Transplantation. Humans. Male

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17211792.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Modak S, Gerald W, Cheung NK: Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol; 2002 Dec;39(6):547-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
  • BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is an aggressive and often misdiagnosed neoplasm of children and young adults.
  • It is chemotherapy-sensitive, yet patients often relapse off therapy because of residual microscopic disease at distant sites: peritoneum, liver, lymph node, and lung.
  • Monoclonal antibodies selective for cell surface tumor-associated antigens may have utility for diagnosis and therapy of MRD, as recently demonstrated in advanced-stage neuroblastoma (JCO 16: 3053, 1998).
  • We examined DSRCT samples for the expression of two tumor antigens that could serve as possible targets for antibody-based immunotherapeutic approaches.
  • 8H9 recognizes a 58 kDa surface antigen expressed among neuroectodermal, mesenchymal, and epithelial tumors with restricted expression on normal tissues.
  • Both G(D2) and the 58 kDa antigen were localized to tumor cell membrane and stroma.
  • CONCLUSIONS: G(D2) and the novel tumor antigen recognized by 8H9 are potential targets for immunodiagnosis and antibody-based therapy of DSRCT.
  • [MeSH-minor] Adolescent. Adult. Antigens, Surface / analysis. Female. Humans. Immunoglobulin G / therapeutic use. Immunohistochemistry. Immunologic Tests. Male. Middle Aged

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12376975.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 61017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3F8 antibody; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Gangliosides; 0 / Immunoglobulin G; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


17. Msika S, Gruden E, Sarnacki S, Orbach D, Philippe-Chomette P, Castel B, Sabaté JM, Flamant Y, Kianmanesh R: Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients. J Pediatr Surg; 2010 Aug;45(8):1617-21
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients.
  • PURPOSE: Desmoplastic round small cell tumor (DRSCT) is a rare intraabdominal mesenchymal tissue neoplasm in young patients and spreads through the abdominal cavity.
  • Its prognosis is poor despite a multimodal therapy including chemotherapy, radiotherapy, and surgical cytoreduction (CS).
  • hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as an additional strategy in the treatment of peritoneal carcinomatosis; for this reason, we planned to treat selected cases of children with DRSCT using CS and HIPEC.
  • There was no other complication related to HIPEC procedure.
  • CONCLUSIONS: Surgical cytoreduction and HIPEC provide a local alternative approach to systemic chemotherapy in the control of microscopic peritoneal disease in DRSCT, with an acceptable morbidity, and may be considered as a potential beneficial adjuvant waiting for a more specific targeted therapy against the fusion protein.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Injections, Intraperitoneal. Male. Palliative Care. Peritoneum / pathology. Peritoneum / surgery. Treatment Outcome. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713209.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Al Balushi Z, Bulduc S, Mulleur C, Lallier M: Desmoplastic small round cell tumor in children: a new therapeutic approach. J Pediatr Surg; 2009 May;44(5):949-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor in children: a new therapeutic approach.
  • PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare, highly aggressive malignancy with distinctive histologic and immunohistochemical features occurring in a young population with a male predominance.
  • The tumor appears to arise as masses in the abdominal cavity without a clear visceral origin.
  • RESULTS: Three patients (BMT recipients) responded to treatment.
  • CONCLUSION: The patients DSRCT are sensitive to an aggressive combination of chemotherapy, surgical debulking, and radiation therapy, followed by autologous BMT.
  • It appears that this new multifaceted treatment offers good palliation, which may prolong survival and a possible cure.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Pelvic Neoplasms / therapy. Radiotherapy, Adjuvant. Sarcoma, Small Cell / therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 11 / ultrastructure. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 22 / ultrastructure. Combined Modality Therapy. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Oncogene Proteins, Fusion / genetics. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Translocation, Genetic. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433176.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR: Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant; 2006 Jan;37(2):175-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors.
  • The prognosis for many pediatric and young adult patients with solid tumors that have metastasized at the time of diagnosis or have relapsed after therapy remains very poor.
  • The steep dose-response curve of many of these tumors to alkylating agents makes myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) an attractive potential therapy.
  • Patients with a diagnosis of Ewing's sarcoma (ES) or desmoplastic small round cell tumor (DSRCT) had significantly better survival than those with other diagnoses with estimated 3-year OS of 54% (95% CI: 29-79%) for this group of patients (P = 0.03).
  • These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Sarcoma, Ewing / mortality. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Fibroma, Desmoplastic / complications. Fibroma, Desmoplastic / mortality. Fibroma, Desmoplastic / pathology. Fibroma, Desmoplastic / therapy. Follow-Up Studies. Hepatic Veno-Occlusive Disease / etiology. Hepatic Veno-Occlusive Disease / mortality. Humans. Male. Risk Factors. Stem Cell Transplantation / methods. Stem Cell Transplantation / mortality. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273111.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK: Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol; 2000 Nov;35(5):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.
  • We tested the hypothesis that much higher dosing would meet critical goals of salvage therapy: antitumor effect and a lack of toxicity to key organs, so as not to preclude subsequent consolidative treatments needed for cure.
  • PROCEDURE: Patients with resistant pediatric solid tumors received cyclophosphamide 4,200 mg/m(2) by 48 hr infusion, and topotecan 6 mg/m(2) by 72 hr infusion (HD-Cy/Topo).
  • All patients had previously received > or =6 cycles of other therapy, high-dose alkylator-based chemotherapy, and/or etoposide- and doxorubicin-containing regimens.
  • Profound myelosuppression was the major toxicity, but retreatment was possible by day 28, and preliminary results with peripheral blood stem cell collections showed a sparing effect on hemopoietic stem cells.
  • Partial or minor responses were noted in neuroblastoma, desmoplastic small round-cell tumor, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.
  • It may also merit incorporation into frontline treatment protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Female. Humans. Male. Neuroblastoma / drug therapy. Pilot Projects. Sarcoma / drug therapy. Topotecan / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11070479.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


21. Anderson PM, Pearson M: Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep; 2006 Jul;8(4):310-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutic approaches in pediatric and young adult sarcomas.
  • Novel therapy as part of sarcoma treatment schemas can enhance quality of life and is important in improving outcomes of high-risk sarcomas.
  • Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural chemotherapy, aerosol 9-nitrocamptothecin, or protracted irinotecan and temozolomide in Ewing's sarcoma; continuous hyperthermic peritoneal perfusion for malignancy involving the peritoneum, such as desmoplastic small round cell tumor; and ifosfamide with muramyl tripeptide phosphatidyl ethanolamine liposomes in osteosarcoma.
  • These treatments bring improved control of symptoms, including reduction in nausea, mucositis, cardiotoxicity, and central nervous system toxicity.
  • Novel local control measures include embolization before surgery, radiosensitization, anti-vascular endothelial growth factor therapy during chemo-radiotherapy, proton therapy, samarium, thermal ablation (radiofrequency ablation), and cryoablation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / therapy
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Humans. Hypothermia, Induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):440-9 [14998846.001]
  • [Cites] Lancet Oncol. 2005 Feb;6(2):93-102 [15683818.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2004-11 [15774791.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] J Surg Res. 2006 Mar;131(1):26-40 [16154153.001]
  • [Cites] Curr Oncol Rep. 2004 Jul;6(4):315-20 [15161588.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):677-84 [15289869.001]
  • [Cites] Eur J Oncol Nurs. 2005 Mar;9(1):21-32 [15774338.001]
  • [Cites] Mayo Clin Proc. 2003 Feb;78(2):147-55 [12583525.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3597-604 [15908670.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7135-42 [16192597.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2963-9 [8221562.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):182-90 [15717743.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S68-73 [16399436.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):492-8 [15667972.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):631-6 [7884424.001]
  • [Cites] Int J Colorectal Dis. 1999 Apr;14(2):86-94 [10367253.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Int J Clin Oncol. 2005 Dec;10(6):438-40 [16369750.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Mar;21(2):216-22 [15711216.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):189-93 [12407700.001]
  • [Cites] Radiology. 2005 May;235(2):469-77 [15858089.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1433-9 [9762946.001]
  • [Cites] Support Care Cancer. 2004 Aug;12(8):543-9 [15221580.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1287-94 [16109605.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2316-23 [10499599.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):15-22 [16311108.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6895-900 [16203780.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):171-83 [8875708.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):21-8 [15188662.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Methods Mol Med. 2005;111:127-48 [15911977.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Apr;2(4):196-201 [16264934.001]
  • [Cites] Methods Enzymol. 2005;391:71-97 [15721375.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8 [15838394.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):840-8 [14871959.001]
  • [Cites] Oncology. 2004;67(3-4):231-42 [15557784.001]
  • [Cites] Radiology. 2005 Apr;235(1):289-98 [15798173.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):111-9 [16390599.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):401-6 [15800948.001]
  • [Cites] Nutrition. 2002 Mar;18(3):217-21 [11882392.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):997-1000 [12854901.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9 [16203786.001]
  • (PMID = 17254532.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


22. Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM: Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol; 2004 Jun;53(6):482-8
Hazardous Substances Data Bank. LEFLUNOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.
  • PURPOSE: To determine the maximum tolerated dose and the toxicity profile of the PDGF receptor pathway inhibitor SU101 in pediatric patients with refractory solid tumors, and to define the plasma pharmacokinetics of SU101 and its active metabolite SU0020 in children.
  • EXPERIMENTAL DESIGN: Patients between 3 and 21 years of age with CNS malignancy, neuroblastoma, or sarcoma refractory to standard therapy were eligible.
  • One patient with rapidly progressive desmoplastic small round-cell tumor experienced symptomatic improvement and prolonged stable disease.
  • The neurotoxicity observed at the 440 mg/m(2) per day dose level suggests that patients receiving repetitive cycles must be monitored closely, as SU0020 may accumulate over time.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Isoxazoles / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aniline Compounds / blood. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Half-Life. Humans. Magnetic Resonance Imaging. Male. Nitriles / blood. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14999430.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Isoxazoles; 0 / Nitriles; 0 / SU 0020; G162GK9U4W / leflunomide
  •  go-up   go-down


23. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Feb;50(2):254-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Imatinib mesylate is a small molecule inhibitor of certain tyrosine kinases, most notably the chimeric bcr-abl fusion protein found in CML.
  • Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, and synovial sarcomas often overexpress KIT or the PDGF receptor.
  • PROCEDURE: Patients less than 30 years of age with refractory or recurrent Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, synovial sarcomas or GIST were eligible.
  • Responses were assessed according to Response Evaluation Criteria in Solid Tumor (RECIST).
  • Hemorrhagic pleural effusions occurred in seven patients with pulmonary lesions, four of whom had progressive disease at the time of the hemorrhage.
  • CONCLUSION: Imatinib as a single agent at a dose of 440 mg/m(2)/day demonstrated little or no activity as a single agent in children with relapsed or refractory Ewing sarcoma, osteosarcoma, neuroblastoma, or desmoplastic small round cell tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Bone Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Child. Child, Preschool. Female. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Male. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Sarcoma, Synovial / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262795.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


24. Shuper A, Stein J, Goshen J, Kornreich L, Yaniv I, Cohen IJ: Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol; 2000 Jul;15(7):481-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 5-year-old child with desmoplastic small round-cell tumor was treated with a protocol of very-high-dose, short-term chemotherapy, containing HD-CAV (cyclophosphamide, doxorubicin, vincristine, and mesna), ifosfamide, and etoposide.
  • The possibility of this complication should be considered when high-dose ifosfamide treatment is planned for children.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cerebellum / drug effects. Cerebral Cortex / drug effects. Ifosfamide / adverse effects. Nerve Degeneration / chemically induced. Persistent Vegetative State / chemically induced
  • [MeSH-minor] Child, Preschool. Dose-Response Relationship, Drug. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Coma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10921521.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] UM20QQM95Y / Ifosfamide
  •  go-up   go-down


25. Bisogno G, Riccardi R, Scagnellato A, Arcamone G, Miglionico L, Carli M: No effect of irinotecan in patients with resistant desmoplastic small round cell tumor. Pediatr Blood Cancer; 2010 Jan;54(1):182-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No effect of irinotecan in patients with resistant desmoplastic small round cell tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Bone Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Drug Resistance, Neoplasm. Fibroma, Desmoplastic / drug therapy. Sarcoma, Small Cell / drug therapy

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876891.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement